Udit Patel

Udit Patel is an executive director in the Piper Sandler healthcare investment banking group, covering biopharmaceutical companies with a focus on Ophthalmology. Select ophthalmology transactions include the sale of Encore Vision to Novartis, initial public offering of Oyster Point Pharma, public financings involving Avalanche Biotechnologies and Adverum and the recapitalization of Calhoun Vision.
Udit has 12 years of healthcare transaction experience, having successfully executed numerous M&A, equity, debt and equity-linked engagements. During his tenure in investment banking, he successfully represented clients in a wide range of M&A and financing transactions, with an aggregate transaction value exceeding $20 billion and $5 billion respectively. Prior to joining Piper Sandler in 2013, Udit was vice president at UBS Investment Bank in New York, where his responsibilities included mergers and acquisitions as well as general advisory focused on healthcare. Before beginning his investment banking career, Udit was a consultant at Deloitte. Udit graduated with a bachelor’s degree in computer science from Cornell University. He earned a Master of Business Administration degree from the MIT Sloan School of Management.